Imatinib for the adjuvant treatment of gastrointestinal stromal tumours

  • Technology appraisal guidance
  • TA326
  • Published: 

Review decision – April 2018

Decision to move the existing guidance to the static list

We would like to update you on the decision made regarding the review of the existing guidance on  imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326).

Overall, no relevant new evidence was identified that would change the existing recommendations in TA326.

Generic versions of imatinib are now available but do not include an indication for adjuvant treatment of gastrointestinal stromal tumour (GIST). The company has confirmed that no changes in marketing authorisation are anticipated and there have not been any changes to the price.

NICE’s Guidance Executive has decided to proceed with this proposal without consultation.

Consequently TA326 will move to the ‘static list’ of technology appraisals.

Review decision paper

This page was last updated: